Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Darrell R. Borger, PH.D.

TitleInstructor in Medicine
InstitutionMassachusetts General Hospital
DepartmentMedicine
AddressMassachusetts General Hospital
Grj-1008
55 Fruit St
Boston MA 02114
Phone617/632-4747
Fax617/724-9889

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Blaszkowsky LS, Ryan DP, Szymonifka J, Borger DR, Zhu AX, Clark JW, Kwak EL, Mamon HJ, Allen JN, Vasudev E, Shellito PC, Cusack JC, Berger DL, Hong TS. Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Ann Oncol. 2014 Jan; 25(1):121-6.
    View in: PubMed
  2. Akhavanfard S, Vargas SO, Han M, Nitta M, Chang CB, Le LP, Fazlollahi L, Nguyen Q, Ma Y, Cosper A, Dias-Santagata D, Han JY, Bergethon K, Borger DR, Ellisen LW, Pomeroy SL, Haber DA, Iafrate AJ, Rivera MN. Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer. 2014 Jan; 53(1):67-77.
    View in: PubMed
  3. Kerr DA, Lopez HU, Deshpande V, Hornicek FJ, Duan Z, Zhang Y, Rosenberg AE, Borger DR, Nielsen GP. Molecular Distinction of Chondrosarcoma From Chondroblastic Osteosarcoma Through IDH1/2 Mutations. Am J Surg Pathol. 2013 Jun; 37(6):787-95.
    View in: PubMed
  4. Penson RT, Goodman A, Growdon WB, Borger DR, Lee SI, Oliva E. Case records of the Massachusetts General Hospital. Case 14-2013. A 70-year-old woman with vaginal bleeding. N Engl J Med. 2013 May 9; 368(19):1827-35.
    View in: PubMed
  5. Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW, Iafrate AJ, Louis DN. BRAF V600E Mutation Identifies a Subset of Low-Grade Diffusely Infiltrating Gliomas in Adults. J Clin Oncol. 2013 May 10; 31(14):e233-6.
    View in: PubMed
  6. Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 2013 Jan 15; 19(2):480-90.
    View in: PubMed
  7. Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012 Nov 29; 120(23):4649-52.
    View in: PubMed
  8. Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98.
    View in: PubMed
  9. Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol. 2012 Oct; 127(1):141-6.
    View in: PubMed
  10. Borger DR, Zhu AX. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications. Expert Rev Anticancer Ther. 2012 May; 12(5):543-6.
    View in: PubMed
  11. Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, Hoang MP, Iafrate AJ, Cusack JC, Engelman JA, Dias-Santagata D. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012 Mar 1; 18(5):1227-36.
    View in: PubMed
  12. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17(1):72-9.
    View in: PubMed
  13. Ryan RJ, Nitta M, Borger D, Zukerberg LR, Ferry JA, Harris NL, Iafrate AJ, Bernstein BE, Sohani AR, Le LP. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One. 2011; 6(12):e28585.
    View in: PubMed
  14. McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL, Sheikh H, Deyneko I, Ferguson JA, Vathipadiekal V, Birrer MJ, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Macdougall JR, Rueda BR. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS One. 2011; 6(11):e28077.
    View in: PubMed
  15. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-24.
    View in: PubMed
  16. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011 Nov 15; 117(22):5094-102.
    View in: PubMed
  17. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011; 6(3):e17948.
    View in: PubMed
  18. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, Pao W. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011 Jan; 13(1):74-84.
    View in: PubMed
  19. Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, Ellisen LW, Tambouret RH, Rueda BR, Borger DR. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol. 2011 Apr; 121(1):212-7.
    View in: PubMed
  20. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR. Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol. 2010; 8:147.
    View in: PubMed
  21. Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010 Nov 20; 28(33):4953-60.
    View in: PubMed
  22. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010 May; 2(5):146-58.
    View in: PubMed
  23. Growdon WB, Boisvert SL, Akhavanfard S, Oliva E, Dias-Santagata DC, Kojiro S, Horowitz NS, Iafrate AJ, Borger DR, Rueda BR. Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol. 2008 Nov; 111(2):289-97.
    View in: PubMed
  24. Borger DR, Gavrilescu LC, Bucur MC, Ivan M, Decaprio JA. AMP-activated protein kinase is essential for survival in chronic hypoxia. Biochem Biophys Res Commun. 2008 May 30; 370(2):230-4.
    View in: PubMed
  25. Borger DR, Bucur MC, Ivan M and DeCaprio JA. AMP-Activated Protein Kinase Is Essential For Transformed Cell Survival During Extended Hypoxic Stress. Submitted. 2007.
  26. Borger DR, DeCaprio JA. Targeting of p300/CREB binding protein coactivators by simian virus 40 is mediated through p53. J Virol. 2006 May; 80(9):4292-303.
    View in: PubMed
  27. Holley S, Borger D. Energy for living with cancer: preliminary findings of a cancer rehabilitation group intervention study. Oncol Nurs Forum. 2001 Oct; 28(9):1393-6.
    View in: PubMed
  28. Darrell Borger. Acquired resistance to retinoic acid correlates to altered transforming growth factor-beta signaling during late premalignant stages of HPV16-mediated transformation of human keratinocytes. 2001.
  29. Mi Y, Borger DR, Fernandes PR, Pirisi L, Creek KE. Loss of transforming growth factor-beta (TGF-beta) receptor type I mediates TGF-beta resistance in human papillomavirus type 16-transformed human keratinocytes at late stages of in vitro progression. Virology. 2000 May 10; 270(2):408-16.
    View in: PubMed
  30. Borger DR, Mi Y, Geslani G, Zyzak LL, Batova A, Engin TS, Pirisi L, Creek KE. Retinoic acid resistance at late stages of human papillomavirus type 16-mediated transformation of human keratinocytes arises despite intact retinoid signaling and is due to a loss of sensitivity to transforming growth factor-beta. Virology. 2000 May 10; 270(2):397-407.
    View in: PubMed
  31. Patton, Jeffrey R, Gregory S Akerman, Darrell R Borger, Lorine E Brock, Kim E Creek and Lucia A Pirisi. Changes in levels of transcription during in vitro progression of human keratinocytes immortalized with HPV16 DNA. 18th International Papillomavirus Conference. 2000.
  32. Borger, Darrell R, Gregory S Akerman, Amy Baldwin, Lucia A Pirisi and Kim E Creek. Acute HPV16 E6/E7 expression alters SMAD3 protein levels and confers TGF-beta resistance to normal human keratinocytes. 18th International Papillomavirus Conference (poster presentation). 2000.
  33. Borger, D, Y Mi, L Pirisi and KE Creek. Resistance to retinoic acid correlates to reduced expression of the TGF-beta type I receptor during late premalignant stages of HPV16-mediated transformation of human keratinocytes. 90th Annual Meeting of the American Association for Cancer Research (poster discussion). 1999.
  34. Borger, Darrell, Yi-de Mi, Lucia Pirisi and Kim E Creek. Decreased TGF-beta receptor type I expression mediates retinoic acid resistance at late stages of HPV16-mediated premalignant conversion in human keratinocytes. 3rd International TGF-beta Conference of the National Cancer Institute: Biological Mechanisms and Clinical Applications (poster presentation). 1999.
  35. Borger, D, Y Mi, L Pirisi and KE Creek. Retinoic acid resistance in HPV16-immortalized human keratinocytes is not associated with changes in nuclear retinoid receptors. 17th International Papillomavirus Conference. 1999.
  36. Borger, Darrell, Yi-de Mi, Lucia Pirisi and Kim E Creek. Retinoic acid resistance at late premalignant stages of HPV16-mediated transformation of human keratinocytes is partially attributed to reduced expression of the TGF-beta receptor type I. 12th Imperial Cancer Research Fund DNA Tumour Virus Meeting (oral presentation). 1999.
  37. Borger DR, Essig DA. Induction of HSP 32 gene in hypoxic cardiomyocytes is attenuated by treatment with N-acetyl-L-cysteine. Am J Physiol. 1998 Mar; 274(3 Pt 2):H965-73.
    View in: PubMed
  38. Creek, KE, G Geslani, Y Mi, D Borger, LL Zyzak, TSW Engin and L Pirisi. Transforming growth factor-beta and retinoic acid resistance at late stages of human papillomavirus type 16-initiated transformation of human keratinocytes. 89th Annual Meeting of the American Association for Cancer Research. 1998.
  39. Darrell Borger. NAC (N-acetyl-L-cysteine) pretreatment attenuates HSP32 induction in acutely hypoxic primary cardiomyocytes. 1997.
  40. Essig DA, Borger DR, Jackson DA. Induction of heme oxygenase-1 (HSP32) mRNA in skeletal muscle following contractions. Am J Physiol. 1997 Jan; 272(1 Pt 1):C59-67.
    View in: PubMed
  41. Borger, D, D Jackson, K Kim, M Nauerth and D Essig. Induction of an oxygen stress protein mRNA in skeletal muscle during recovery from repetitive contractions. FASEB (poster presentation). 1995; 9(3):A350.
  42. Essig, DA, DA Jackson and DR Borger. A heme oxygenase mRNA is induced in skeletal muscle following 3 hours of nerve stimulation. Med Sci Sport Ex. 1994; 26:S94.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Borger's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_